PharmaTelevision - Spinifex: CEO, Tom McCarthy explains their new approach to the treatment of pain.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Spinifex: CEO, Tom McCarthy explains their new approach to the treatment of pain.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Tom McCarthy, CEO of Spinifex.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Spinifex's focus on developing new drugs for pain

Paul Larsmon :

Hello and welcome to PharmaTelevision News Review here at BioPartnering Europe 2011. Well with me today is Tom McCarthy, the CEO and MD of Spinifex an Australian biotech. Tom, tell us a little bit about your company.

Tom McCarthy:

Well Spinifex is focused on developing new drugs for pain and particularly neuropathic pain which is a group of painful conditions that are a result of dysfunction to the nervous system , so a headline neuropathic pain indication is diabetic neuropathy which really means a complication associated with the disease of diabetes and it means you have diabetes you have problems with your peripheral vasculature and you have therefore problems with your peripheral nervous system as well and that leads to pain, that leads to hypersensitivity and that's a type of indication that we are trying to treat.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Paul Larsmon

Paul Larsmon has worked as a broadcast television journalist for 25 years, covering general news, business and politics. He has been both presenter and producer in several news broadcasters, including the major British television news company ITN. He joined PharmaTelevision as Executive Producer earlier this year and has been responsible for getting PTV News launched.

Tom McCarthy

CEO

Tom McCarthy currently serves as Chief Executive Officer & Managing Director of Spinifex Pharmaceuticals. He has over 16 years experience in drug discovery and development and has been responsible for a variety of drug development programs under Investigation New Drug applications (IND) with the United States Food and Drug Administration (FDA). Dr. McCarthy prior positions include Vice President, Drug Development at Starpharma Pty Ltd where he was responsible for Starpharma's projects from lead candidate optimization/selection through to IND submission and clinical trials. In this role he managed the development for SPL7013 Gel (VivaGel) and was responsible for securing in excess of US$25M of United States National Institutes of Health (NIH) funding for Starpharma's drug development programs. Dr. McCarthy completed a Bachelor of Science (Honours) degree and a Ph.D. in medicinal chemistry at Monash University in 1989 and 1993 respectively and has completed post-doctoral training at the University of Oxford.

PharmaVentures

PharmaVentures is a company that has proven success in deals and alliances. PharmaVentures offers: Over 18 years of healthcare industry experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments Over 40 specialist advisors, analysts and researchers Skills honed in many countries - 80% of its business comes from outside the UK.

Spinifex Pharmaceuticals

Spinifex Pharmaceuticals is an Australian biotechnology company developing new drug candidates for the treatment and management of pain. Established in 2005 and based in Melbourne, Spinifex has applied its world-class drug development capabilities to advance product candidates. Its lead product EMA401 is under development as a potential first-in-class oral treatment for neuropathic pain and related symptoms without CNS side effects. Spinifex is conducting Phase 2 clinical trials with EMA401 in a number of neuropathic pain conditions. Spinifex investors are GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest.